	US 11,667,934 B2
	Platform for expressing protein of interest in liver
Seokjoong Kim, Seoul (KR); Dong Woo Song, Seoul (KR); Kyu Jun Lee, Seoul (KR); Jung-Min Lee, Gyeongsangbuk-do (KR); and Un-Gi Kim, Seoul (KR)
Assigned to TOOLGEN INCORPORATED, Seoul (KR)
Appl. No. 16/623,017
Filed by TOOLGEN INCORPORATED, Seoul (KR)
PCT Filed Jun. 15, 2018, PCT No. PCT/KR2018/006803 § 371(c)(1), (2) Date Dec. 16, 2019, PCT Pub. No. WO2018/231018, PCT Pub. Date Dec. 20, 2018.
Claims priority of provisional application 62/520,103, filed on Jun. 15, 2017.
Claims priority of provisional application 62/662,907, filed on Apr. 26, 2018.
Prior Publication US 2021/0095316 A1, Apr. 1, 2021
Int. Cl. C12N 15/90 (2006.01); C12N 9/22 (2006.01); C12N 9/64 (2006.01); C12N 15/11 (2006.01); C12N 15/86 (2006.01); A61K 38/17 (2006.01); A61P 7/04 (2006.01); A61K 48/00 (2006.01); C07K 14/775 (2006.01); C12N 15/113 (2010.01)

CPC C12N 15/907 (2013.01) [C12N 9/22 (2013.01); C12N 9/644 (2013.01); C12N 15/11 (2013.01); C12N 15/86 (2013.01); C12N 2310/20 (2017.05); C12N 2750/14143 (2013.01); C12N 2800/80 (2013.01)]

15 Claims

1. A Liver bio-factory platform (LBP) system for expressing a transgene comprising,

an engineered hepatocyte including the transgene artificially inserted in a region encoding a highly expressed and secretory gene on a genome of hepatocyte,

wherein the highly expressed and secretory gene is haptoglobin (HP) gene present in the genome of hepatocytes,

wherein the transgene is expressed higher compared to before insertion, or the transgene is newly expressed in hepatocyte, and

wherein a protein produced by expressing the transgene is present in the hepatocyte or secreted out of the hepatocyte.